dacomitinib (vizimpro) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

  • Now
Dacomitinib is an oral, once-daily, pan-HER inhibitor. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomtinib is being evaluated in phase 3 clinical trials against nonsmall-cell lung cancer. Direct comparison with erlotinib did not show superiority of dacomtinib, but subgroup analysis have demonstrated that subgroup with exon 19 deletion had favorable outcomes with dacomitinib. In addition to nonsmall-cell lung cancer dacomtinib is being evaluated against esophagus, head and neck and other neoplasms. Due to its ability to pass through blood-brain barrier, dacomitinib can be used to treat brain tumors.   NCATS

  • SMILES: COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN4CCCCC4
  • Mol. Mass: 469.95
  • ALogP: 5.16
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$292.0620 - $404.2573
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

dacomitinib | dacomitinib anhydrous | dacomitinib hydrate | pf00299804 | pf 00299804 | pf-00299804 | pf-00299804-03 | pf-299804


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue